Novartis AG (NYSE:NVS)
| 89.52 BATS BZX Real-Time Price As of 10:07am ET |  -1.03 / -1.14%Today’s Change | 79.34 Today|||52-Week Range 98.52 | +2.34% Year-to-Date |
Latest NVS News | Press Releases
| Dodge & Cox Global Stock Fund's 4th-Quarter Commentary Jan 17 / GuruFocus News - Paid Partner Content | Where Will Biogen Be in 5 Years? Jan 15 / MotleyFool.com - Paid Partner Content |
| Dodge & Cox Stock Fund's 4th-Quarter Commentary Jan 17 / GuruFocus News - Paid Partner Content | Is electroCore a Good Stock to Add to Your Healthcare Portfolio? Jan 14 / StockNews.com - Paid Partner Content |
| Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business Jan 17 / Zacks.com - Paid Partner Content | Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug Jan 11 / Zacks.com - Paid Partner Content |
| GlaxoSmithKline - Catalysts Ahead Jan 17 / GuruFocus News - Paid Partner Content | Why Molecular Partners Stock Crushed the Market Today Jan 10 / MotleyFool.com - Paid Partner Content |
| 3 Top Biotech Stocks to Buy Right Now Jan 15 / MotleyFool.com - Paid Partner Content | Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies Jan 07 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 90.55 |
| Today’s open | 89.53 |
| Day’s range | 89.50 - 89.80 |
| Volume | 295,055 |
| Average volume (3 months) | 2,323,092 |
| Market cap | $202.6B |
Data as of 10:07am ET, 01/18/2022
Growth & Valuation
| Earnings growth (last year) | +15.34% |
| Earnings growth (this year) | -92.09% |
| Earnings growth (next 5 years) | +6.89% |
| Revenue growth (last year) | +2.44% |
| P/E ratio | 20.7 |
| Price/Sales | 4.46 |
| Price/Book | 3.61 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | -0.19 | -0.23% |
| AZNAstraZeneca | +0.55 | +0.93% |
| LLYEli Lilly and Co | +1.08 | +0.44% |
| NVONovo Nordisk | -0.13 | -0.13% |
Data as of 10:07am ET, 01/18/2022
Financials
| Next reporting date | April 26, 2022 |
| EPS forecast (this quarter) | $1.43 |
| Annual revenue (last year) | $48.7B |
| Annual profit (last year) | $8.1B |
| Net profit margin | 16.59% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Basel, Basel-stadt (basle Town) |
Forecasts
